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Edited by Berend WieringaAbstract Matrix metalloproteinase (MMP)-7 is considered to
play essential roles in cancer progression. We examined the eﬃ-
cacy of auraptene, a citrus coumarin derivative, for suppressing
MMP-7 expression in the human colorectal adenocarcinoma cell
line HT-29. Auraptene remarkably inhibited the production of
proMMP-7 protein, without aﬀecting its mRNA expression
level. Rapamycin, an inhibitor of mammalian target of rapamycin
(mTOR), showed similar results, suggesting that auraptene sup-
presses mTOR-dependent proMMP-7 translation. Interestingly,
however, auraptene showed no eﬀects on the activation of Akt/
mTOR signaling, whereas the phosphorylation levels of 4E bind-
ing protein (4EBP)1 and eukaryotic translation initiation factor
(eIF)4B were substantially decreased. In addition, auraptene
remarkably dephosphorylated constitutively activated extracellu-
lar signal-regulated kinase (ERK)1/2. Transfection of ERK1/2
siRNA led to a signiﬁcant reduction of proMMP-7 protein pro-
duction as well as of the phosphorylation of eIF4B. These results
demonstrate that auraptene targets the translation step for
proMMP-7 protein synthesis by disrupting ERK1/2-mediated
phosphorylation of 4EBP1 and eIF4B.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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We previously identiﬁed auraptene (7-geranyloxycoumarin)
as an inhibitor of 12-O-tetradecanoylphorbol-13-acetate
(TPA)-induced Epstein–Barr virus activation [1]. This com-
pound occurs in a variety of citrus fruit [1–3]. Auraptene has
also been shown to markedly suppress TPA-induced free rad-
ical generation [1], and attenuate the expression of inducibleAbbreviations: 4EBP, 4E binding protein; AP, activator protein; AUR,
auraptene; DMEM, Dulbecco’s modiﬁed Eagle’s medium; DMSO,
dimethyl sulfoxide; eIF, eukaryotic initiation factor; ERK, extracellu-
lar signal-regulated kinase; GAPDH, glyceraldehyde-3-phosphate
dehydrogenase; IC50, 50% inhibitory concentration; JNK, c-jun
N-terminal kinase; MEK, mitogen-activate protein kinase/extracellular
signal-regulated kinase; MMP, matrix metalloproteinase; mTOR,
mammalian target of rapamycin; NOB, nobiletin; PKC, protein kinase
C; RAP, rapamycin; RT-PCR, reverse transcription-polymerase chain
reaction; S6K, p70 S6 kinase; TPA, 12-O-tetradecanoylphorbol-13-
acetate; UMB, umbelliferone
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doi:10.1016/j.febslet.2006.08.072nitric oxide synthase and cyclooxygenase-2 in lipopolysaccha-
ride-stimulated inﬂammatory cells [4]. In addition, anti-tumor
promoting [1] and anti-inﬂammatory [4] activities have been
observed in mouse skin, and yet it suppressed experimental
carcinogenesis [5–8]. Of note, studies by our group and Curini
et al. indicate that the anti-inﬂammatory activity of auraptene
is critically dependent on the presence of the geranyloxyl moi-
ety [1,4,9]. Together, these results support the hypothesis that
auraptene is a promising food phytochemical for anti-inﬂam-
matory and anti-carcinogenic strategies, though its action
mechanisms are not fully understood.
Matrix metalloproteinase (MMP)-7, also referred to as
matrilysin, is a member of the MMP family. Many groups
have reported that the oncogenic transcription factors activa-
tor protein (AP)-1 and b-catenin synergistically increase
MMP-7 gene expression [10]. Further, it has been demon-
strated thatMMP-7 is highly expressed in many neoplastic tis-
sues, such as colon and gastric samples [11]. The correlation of
MMP-7 expression with invasion and metastasis has been also
reported [12,13]. Of note, increased MMP-7 expression levels
were detected in the early phase of colorectal carcinogenesis
[14], and tumor multiplicity and diameter in the intestines of
MMP-7 deﬁcient Min/+ mice were shown to be markedly re-
duced as compared with those in wild-type Min/+ mice [15].
In addition, MMP-7 may confer resistance to apoptosis and
a growth advantage by cleaving the Fas ligand [16] and insu-
lin-like growth factor binding protein-3 [17], respectively. Also,
it may stimulate cell migration and invasion through the re-
lease of soluble E-cadherin fragments [18]. These ﬁndings
strongly suggest that MMP-7 contributes to tumor progression
as well as invasion and metastasis, and is thus a distinct target
for chemoprevention and chemotherapy.
Given that auraptene has shown prominent chemopreventive
activities in rat colon carcinogenesis [7,8], we attempted to deter-
mine whether its application causes a decrease in proMMP-7
production in HT-29 human colorectal cancer cells. Herein,
we present intriguing molecular mechanisms by which aurap-
tene suppresses the translation steps of proMMP-7 protein.2. Materials and methods
2.1. Chemicals
Auraptene and nobiletin were puriﬁed (each >95%) as previously re-
ported [1,19]. Dulbecco’s modiﬁed Eagle’s medium (DMEM), Trizma
Base (Tris), protease inhibitor cocktail, phosphatase inhibitor cocktail
2 and umbelliferone were obtained from Sigma-Aldrich (St Louis,
MO). DMEM without serum and phenol red, Lipofectamine 2000,
and Opti-MEM I were purchased from Invitrogen (Carlsbad, CA).
ECL Western blotting detection reagents were obtained fromblished by Elsevier B.V. All rights reserved.
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MOL International L. P. (Plymouth Meeting, PA). All other reagents
used were purchased from Wako Pure Chemicals (Osaka, Japan), un-
less speciﬁed otherwise.
2.2. Antibodies
The anti-hMMP-7 antibody (F-82) was purchased from Daiichi Fine
Chemical (Toyama, Japan). Antibodies against b-actin (C-11), c-myc
(9E10), and cyclin-dependent kinase (CDK)4 (H-22) were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). The anti-Bcl-x anti-
body was from BD Biosciences (San Jose, CA). Antibodies directed
against mitogen-activated protein kinase/extracellular signal-regulated
kinase (MEK)1/2 (#9122), Pi-MEK1/2 (Ser217/221, #9121), ERK1/2
(#9102), Pi-ERK1/2 (Thr202/Tyr204, #9101), c-jun N-terminal kinase
(JNK)1/2 (#9252), Pi-JNK1/2 (Thr183/Tyr185, #9251), p38 (#9212),
Pi-p38 (Thr180/Tyr182, #9211), Akt (#9272), Pi-Akt (Thr308,
#9271; Ser473, #9275), mTOR (#2972), Pi-mTOR (Ser2448, #2971),
p70 S6 kinase (S6K)1 (#9202), Pi-S6K1 (Thr389, # 9206), 4EBP1
(#9452), Pi-4EBP1 (Thr37/46, #9459; Ser65, #9451; Thr70, #9455),
S6 (#2212), Pi-S6 (Ser240/244, #2215), eIF4B (#3592), and Pi-eIF4B
(Ser422, #3591), as well as horseradish peroxidase (HRP)-conjugated
anti-rabbit antibody (#7074), were obtained from Cell Signaling
Technology (Beverly, MA). HRP-conjugated anti-mouse (P0447) and
anti-goat (P0449) antibodies were purchased from Dako (Glostrup,
Denmark).
2.3. Cell culture
HT-29 cells were purchased from American Type Culture Collection
(ATCC, Manassas, VA) and cultured in DMEM supplemented with
10% fetal bovine serum (Biological Industries, Kibbutz Beit Haemek, Is-
rael), 100 U/ml of penicillin, and 100 lg/ml of streptomycin at 37 C in a
humidiﬁed atmosphere with 5% CO2. The test compounds were dis-
solved in dimethyl sulfoxide (DMSO) and added to the cells at a ﬁnal
concentration of 0.05% (v/v) DMSO. No signiﬁcant cytotoxicity was
seen in any of the experiments, as shown by 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay (data not shown).
2.4. Western blotting
Sample preparation was performed as described previously [20].
Brieﬂy HT-29 cells were lysed in lysis buﬀer supplemented with prote-
ase inhibitor cocktail and phosphatase inhibitor cocktail 2. The lysates
were sonicated to remove viscosity and kept at 20 C until the assay.
The supernatant protein was precipitated and resuspended in 40 lL of
sample buﬀer. Ten micrograms of protein from the cell lysate and
10 lL of supernatant protein were subjected to Western blotting for
proMMP-7 analysis, while 60 lg of protein was used in the other
experiments. The proteins were separated on 10% (for proMMP-7
analysis) or 12.5% (other experiments) polyacrylamide gels, and trans-
ferred to Immobilon-P membranes (Millipore, Billerica, MA). After
blocking with Block Ace (Snow Brand Milk Products, Tokyo, Japan)
for 1 h, the membranes were reacted with the appropriate speciﬁc pri-
mary antibody (1:1000), followed by the corresponding HRP-conju-
gated secondary antibody (1:1000). The blots were developed using
ECL Western blotting detection reagents. Band intensities were quan-
tiﬁed using NIHimage. b-Actin was used as the internal standard.2.5. Reverse transcription-polymerase chain reaction (RT-PCR)
RT-PCRanalysis was done as described previously [20]. Brieﬂy, Total
RNAwas extracted using aQIAshredder andRNeasyMiniKit (Qia-
gen, Hilden, Germany), according to the manufacturer’s instructions.
Then, cDNA was synthesized from 1 lg of total RNA using an RNA
PCR Kit (AMV) Ver. 2.1 (TaKaRa Bio, Shiga, Japan), with an Oligo-
dT adaptor primer. PCRwas carried out in PCR reaction mixture using
a thermal cycler PTC-100 (MJResearch,Watertown,MA). PCR ampli-
ﬁcation of cDNA fromMMP-7 or glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) was performed using each primer [20]. The primers
for c-myc (5 0-TCCAGCTTGTACCTGCAGGATCTGA-3 0 and 5 0-
CCTCCAGCAGAAGGTGATCCAGACT-3 0; 30 cycles at 94 C for
30 s, 65 C for 1 min, and 72 C for 1 min; 338 bp, Proligo), for CDK4
(5 0-ATCAGCACAGTTCGTGAGGTGGC-3 0 and 5 0-AGCTCGG-
TACCAGAGTGTAACAAC-3 0; 27 cycles at 94 C for 1 min, 55 C
for 1 min, and 72 C for 1 min; 396 bp, Proligo), Bcl-xL (5 0-CCA-
GAAGGGACTGAATCG-30 and 5 0-CCTTGTCTACGCTTTCCAC-
3 0; 30 cycles at 94 C for 1 min, 50 C for 1 min, and 72 C for 1 min;361 bp, Proligo) and b-actin (5 0-CTTCCCCTCCATCTTGGGGC-30
and 5 0-GTTTCGTGGATGCCACAGGAC-30; 28 cycles at 94 C for
90 s, 60 C for 90 s, and 72 C for 90 s; 730 bp, Proligo) were used at a
ﬁnal concentration of 0.2 lM [21–24]. As internal standards, GAPDH
and b-actin were used. The PCR products were electrophoresed on 3%
agarose gels and stained with 0.01% SYBR Gold (Molecular probes,
Eugene, OR).
2.6. RNA interference
HT-29 cells were transfected with 60 pmol of non-speciﬁc control
siRNA, or human ERK1 or ERK2 (Santa Cruz Biotechnology, Santa
Cruz, CA) siRNA, using Lipofectamine 2000 in Opti-MEM I for 6 h.
After 12 h of recovery time in the culture medium, cells were treated
with 0.05% (v/v) DMSO in serum-free medium for 24 h, after which
the cell lysates and supernatants were subjected to Western blotting
analysis as described above.3. Results
3.1. Inhibition of proMMP-7 protein production
We initially examined the eﬀects of auraptene on the produc-
tion of proMMP-7 protein in HT-29 human colorectal adeno-
carcinoma cells. As shown in Fig. 1A, treatment with auraptene
decreased the levels of both intracellular and extracellular
proMMP-7 production, with IC50 values of 2.8 and 3 lM,
respectively. In contrast, umbelliferone, an auraptene analogue
lacking the geranyloxyl group, had no eﬀect even at a concen-
tration of 100 lM. Further, proMMP-7 protein was spontane-
ously secreted from vehicle-treated cells into the medium from 6
to 24 h, whereas 25 lM of auraptene suppressed that secretion
by 78% after 24 h (P < 0.05) (Fig. 1B). In the vehicle-treated
cells, intracellular proMMP-7 protein continuously increased
from 6 to 24 h, while that in the cells treated with auraptene
decreased time-dependently until it was scarcely detectable
after 18 h (98% inhibition, P < 0.0005) (Fig. 1C). We also
examined the eﬀects of auraptene on MMP-7 mRNA expres-
sion by using RT-PCR. Interestingly, neither auraptene nor
umbelliferone had an eﬀect on MMP-7 mRNA expression,
while nobiletin [20] abolished it (Fig. 1D), suggesting that
auraptene regulates the production of proMMP-7 protein by
aﬀecting the protein translation process.
3.2. Rapamycin decreased proMMP-7 protein production
The mammalian target of rapamycin (mTOR), a Ser/Thr
kinase, is considered to play a crucial role as the regulator of
protein translation signaling (for review, see Ref. [25]). We
attempted to determine whether rapamycin, an mTOR inhibi-
tor, decreases the translation of proMMP-7 protein in HT-29
cells. The agent suppressed both extracellular and intracellular
proMMP-7 production (30–63% and 33–34% inhibition,
respectively) in a dose-dependent manner (Fig. 1E), whereas
there was no eﬀect on mRNA expression.
3.3. Auraptene suppressed the phosphorylation of 4E binding
protein (4EBP1) and eukaryotic initiation factor (eIF4B),
but not of S6K1 and S6
We also investigated the eﬀects of auraptene and rapamycin
on the phosphorylation status of 4EBP1, S6K1, S6, and
eIF4B, which are known to have key roles in mTOR-regulated
translation [25]. HT-29 cells were treated with the vehicle, rap-
amycin, or auraptene for 1, 3, and 6 h, after which the phos-
phorylation state of the translation initiation factors was
analyzed by Western blotting (Fig. 2). The phosphorylation
Fig. 1. (A–C) Auraptene decreased the levels of proMMP-7 protein in HT-29 cells in dose- and time-dependent manners. (A) HT-29 cells were
treated with DMSO, various concentrations (0–50 lM) of AUR (auraptene) or UMB (umbelliferone, 100 lM) for 24 h. Thereafter extracellular
(open bars) and intracellular (closed bars) proMMP-7 proteins were analyzed by Western blotting (see Section 2). The band intensities of intracellular
proMMP-7 were corrected with that of b-actin as the internal standard. *1–*3Signiﬁcant diﬀerence from vehicle-treated cells as shown by Student’s t-
test (P < 0.05, P < 0.01, and P < 0.005, respectively). (B and C) HT-29 cells were treated with DMSO (closed squares) or AUR (25 lM, open circles)
for the indicated times. Following the speciﬁed times, extracellular (B) and intracellular (C) proteins were collected and analyzed by Western blotting
as described above. *1,*2Signiﬁcant diﬀerence from DMSO-treated cells at each time point as shown by Student’s t-test (P < 0.05 and P < 0.01,
respectively). (D) Auraptene had no eﬀects on the expression ofMMP-7mRNA in HT-29 cells. Total RNA in HT-29 cells treated with DMSO, AUR
(50 lM), UMB (100 lM) or NOB (nobiletin, 100 lM) for 24 h was isolated, then subjected to RT-PCR (see Section 2). The PCR products ofMMP-7
and the internal standard (GAPDH) were electrophoresed on 3% agarose gels, and detected by SYBR Gold staining. (E) Rapamycin inhibited the
translation of proMMP-7 protein in HT-29 cells in a concentration-dependent manner. HT-29 cells were incubated with DMSO or RAP (rapamycin,
0–0.5 lM) for 24 h. Extracellular (open bars) and intracellular (closed bars) proteins were analyzed by Western blotting. Asterisk indicates signiﬁcant
diﬀerence from control group as shown by Student’s t-test (P < 0.01). The level of MMP-7 mRNA in HT-29 cells was measured using RT-PCR, as
described above. Experiments were performed independently three times and data are shown as the means ± S.D.
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Fig. 2. Rapamycin dephosphorylated 4EBP1, S6K1, and S6, whereas
auraptene decreased the phosphorylation of 4EBP1 and eIF4B in HT-
29 cells. HT-29 cells were treated with DMSO, RAP (0.5 lM) or AUR
(25 lM) for the indicated times, then cell lysates were analyzed by
Western blotting using speciﬁc antibodies (see Section 2). Results
shown are representative of three independent experiments.
Fig. 3. Auraptene suppressed ERK1/2 constitutive activation, but not
MEK1/2, Akt, mTOR, JNK1/2, or p38 in HT-29 cells. HT-29 cells
were treated with DMSO or AUR (25 lM) for the indicated times,
then cell lysates were analyzed by Western blotting speciﬁc antibodies
(see Section 2). Results shown are representative of three independent
experiments.
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cells was slightly decreased, whereas rapamycin potentiated
dephosphorylation at Thr37/46 and Thr70, but not at Ser65.
Similar observations were obtained when the cells were treated
with auraptene, except that dephosphorylation did not occur
at the Ser65 residue. Treatment with rapamycin increased the
levels of non-phosphorylated active 4EBP1 as compared with
the control during 1–6 h, while that with auraptene did so dur-
ing 1–3 h, and it was diminished at 6 h. Further, rapamycin
substantially dephosphorylated S6K1 at Thr389 and S6 at
Ser240/244 from 1 to 6 h, whereas it did not have an eﬀect
on the phosphorylation status of eIF4B at Ser422. Interest-
ingly, auraptene exhibited inverse eﬀects on the phosphoryla-
tion status of S6K1, S6, and eIF4B as compared to rapamycin.
3.4. Auraptene suppressed ERK1/2, but not Akt/mTOR
The diﬀering results obtained with auraptene and rapamycin
led us to examine whether auraptene disrupts the Akt/mTOR
pathway. In vehicle-treated cells, both Akt and mTOR were
consistently active during 1–6 h (Fig. 3), while auraptene
(25 lM) did not have a signiﬁcant eﬀect on the expression lev-
els of either the active or inactive forms. An increasing body of
evidence has implicated the pivotal roles of ERK1/2 in transla-
tion initiation signaling [26,27]. It is also interesting to note
that TPA-activated ERK1/2 may phosphorylate 4EBP1 at
multiple amino acid residues [26]. Therefore, we examined
the eﬀects of auraptene on the phosphorylation state of
MEK1/2 and ERK1/2, as well as that of other members of
the mitogen-activated protein kinase (MAPK) family, such
as JNK1/2 and p38. The active forms of MEK1/2 and 3 diﬀer-
ent MAPKs were consistently detected in vehicle-treated cellsduring 1–6 h. Although it had a near negligible eﬀect on the
activation of JNK1/2 and p38, auraptene markedly dephos-
phorylated ERK1/2 during 1–6 h. Surprisingly, the level of
MEK1/2 phosphorylation, which is the determinant of ERK
activation in many cell types, was fairly constant with or with-
out auraptene exposure.
3.5. ERK1/2 knockdown led to a marked reduction in
proMMP-7 protein
To ascertain the involvement of auraptene-induced ERK1/2
inactivation in the suppression of proMMP-7 translation, we
determined the level of proMMP-7 protein when ERK1/2
expression was decreased by RNAi (Fig. 4A). Control siRNA
did not show any notable eﬀects, whereas individual treat-
ments with ERK1 and ERK2 siRNA led to decreases in each
band intensity of 71% and 79%, respectively, with a reduction
of 84% achieved with combined ERK1/2 siRNA treatment, as
compared to the control. It is notable that ERK1/2 knock-
down and, to a lesser extent ERK2 knockdown, resulted in sig-
niﬁcant proMMP-7 suppression in a range of 59–100%.
Interestingly, both ERK2 and ERK1/2 knockdown decreased
the phosphorylation level of eIF4B in a range of 35–72% with-
out aﬀecting the expression of the inactive form. On the other
Fig. 4. (A) Knockdown of ERK1/2 by RNA interference was
associated with a reduction of proMMP-7 production in HT-29 cells.
HT-29 cells were transfected with control double-strand RNA (con-
trol), or speciﬁc siRNA to ERK1 and ERK2 for 6 h. Following a
recovery time of 12 h, cells were treated with the vehicle for 24 h, then
cell lysates and supernatants were subjected to Western blotting (see
Section 2). Levels of ERK1/2, eIF4B, and proMMP-7 proteins were
analyzed using non-phospho-speciﬁc and phospho-speciﬁc antibodies
for each. (B) Auraptene and rapamycin suppressed the expression of c-
myc, CDK4, and Bcl-xL during the translational step, whereas these
compounds exhibited no inﬂuence on the respective mRNA levels. HT-
29 cells were treated with DMSO, RAP (0.5 lM) or AUR (25 lM) for
24 h, then cell lysates and total mRNA were analyzed by Western
blotting and RT-PCR, respectively, as described above. Results shown
are representative of three independent experiments.
Fig. 5. Proposed schema of molecular mechanisms by which AUR
suppresses proMMP-7 production in HT-29 human colorectal adeno-
carcinoma cells. Protein translation is regulated by both Akt/mTOR
and MEK/ERK signaling pathways. Akt, mTOR, and the downstream
factors of mTOR, such as 4EBP1, S6K1, S6, and eIF4B, are
phosphorylated in a constitutive manner. Rapamycin, an mTOR
inhibitor, decreases proMMP-7 production by targeting those down-
stream molecules, except for eIF4B. In contrast, auraptene induces the
dephosphorylation of ERK1/2 without an eﬀect on Akt, mTOR, and
MEK1/2, which is probably associated with the reduced phosphory-
lation of 4EBP1 and eIF4B. The present results showed that ERK1/2
knockdown by siRNA led to a decrease in eIF4B and MMP-7. In
addition, eIF4B may be regulated by ERK1/2 and not S6K1 in HT-29
cells.
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both intracellular proMMP-7 and phosphorylated eIF4B by
1.6- and 2.4-fold, respectively.
3.6. Auraptene and rapamycin inhibited the translation of c-myc,
CDK4, and Bcl-xL
We also investigated the eﬀects of auraptene on the mRNA
expression of c-myc, CDK4, and Bcl-xL, each of which are
regulated at the translational level and whose protein
expression is known to be decreased by rapamycin [28–30].
As expected, both auraptene and rapamycin markedly inhib-
ited the translation of those proteins, whereas no signiﬁcant
changes in the mRNA expression levels were observed
(Fig. 4B).4. Discussion
MMP-7 is known to be an accelerator of cancer invasion
and metastasis [12,13], and is also associated with the progres-
sion of tumorigenesis [14,15]. Thus, suppressants or inhibitors
of MMP-7 are considered to be potential agents for chemopre-
vention and chemotherapy strategies, though studies on the
identiﬁcation of such compounds are limited [31,32]. Those re-
sults together with the lack of synthetic MMP-7-speciﬁc inhib-
itors, point to the large impact that discovery of natural or
synthetic compounds that target MMP-7 would yield. To
achieve that goal, we recently investigated the citrus poly-
methoxyﬂavonoid nobiletin and found that it down-regulated
MMP-7 expression in HT-29 cells via the suppression of AP-
1 DNA binding activity [20]. In addition, the present study
demonstrated for the ﬁrst time that auraptene markedly inhib-
its proMMP-7 production in the same cell line, while umbellif-
erone was completely inactive toward the proMMP-7
production, which is consistent with our previous studies
[1,4]. Thus, the role of the geranyloxyl group is essential for
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the cellular uptake eﬃciency of this natural compound, as pre-
viously suggested in a study of macrophages [4]. In addition,
the present ﬁndings led us to hypothesize that anti-tumor pro-
moting activity in a variety of experimental systems [1,5–8]
may be partly due to MMP-7 suppression.
Protein translation is rigorously regulated by a complex
mechanism (Fig. 5). Activation of mTOR through the phos-
phatidylinositol 3 0-kinase/Akt pathway leads to the phosphor-
ylation of 4EBP1 and S6K1, while hypo-phosphorylated
4EBP1 inhibits the translation by interrupting the binding of
eIF4E (a cap-structure binding protein) with eIF4G (a scaf-
folding protein) to form an eIF4F translation initiation com-
plex that consists of eIF4A, 4G, and 4E. Following that
formation, eIF4A unwinds the secondary structure in the 5 0-
untranslated region of the target mRNA to facilitate the bind-
ing of ribosome. On the other hand, activated S6K1 causes
phosphorylation of S6 [33] and eIF4B [34], which then produce
an increase in eIF4A RNA helicase activity [35]. Of paramount
importance, ERK1/2 is considered to be the regulator of pro-
tein translation signaling, since it increases eIF4E activity
through 4EBP1 phosphorylation [26]. In addition, the active
Src increased the level of b-catenin translation by enhancing
eIF4E phosphorylation through the MEK/ERK pathway
[27]. Together, mTOR and ERK1/2 are the master regulators
of translation initiation.
It is interesting to note that auraptene suppressed proMMP-
7 production in concentration- and time-dependent manners,
whereas it had no eﬀect on MMP-7 mRNA expression, sug-
gesting that it targets proMMP-7 translation. Both rapamycin
and auraptene enhanced the dephosphorylation of Pi-4EBP1
at Thr37/46 and Thr70, but not at Ser65 (Fig. 2). The decrease
in Pi-4EBP1 level in DMSO-treated cells may have been due to
an eﬀect of the vehicle, because DMSO at high concentrations
(>0.1%) reduced the level of proMMP-7 protein (data not
shown). Further, the decrease in phosphorylated S6 was prob-
ably derived from serum starvation [36]. However, rapamycin
suppressed the activation of S6K1 and S6, but not eIF4B,
while auraptene selectively dephosphorylated Pi-eIF4B at
Ser422 without aﬀecting the phosphorylation status of S6K1.
Recent report showed that during the process of S6K1-induced
eIF4B phosphorylation, eIF4A was recruited into the transla-
tion initiation complex [37]. Our present observations suggest
that auraptene suppresses proMMP-7 protein translation,
which may result from disruption of the eIF4F complex for-
mation for eIF4A-dependent mRNA unwinding by targeting
4EBP1 and eIF4B. It is noteworthy that auraptene remarkably
suppressed the activation of ERK1/2, but not of Akt/mTOR,
and that the knockdown of ERK1/2 by siRNA signiﬁcantly re-
duced the production of both extracellular and intracellular
proMMP-7 protein. From those results, we speculated that
auraptene disrupts MMP-7 translation by acting on the
ERK1/2-regulated pathway, but not that regulated by Akt/
mTOR.
Our results with RNAi demonstrated that the level of eIF4B
phosphorylation was also decreased in ERK1/2-reduced cells
(Fig. 4A). Further, ERK1 knockdown increased both intracel-
lular proMMP-7 and phosphorylated eIF4B, possibly associ-
ated with an increase in the unidentiﬁed substrate(s) of
ERK1, which may also be utilized by active ERK2 and medi-
ate the phosphorylation of eIF4B for MMP-7 production. This
notion may be supported by our current results with a combi-nation of ERK1/2 siRNA, which abolished that production.
As noted above, auraptene-suppressed ERK1/2 activation
was not correlated with the expression level of active MEK1/2
(Fig. 3). Conversely, a MEK1/2 selective inhibitor did not
suppress MMP-7 (data not shown), highly suggesting that
MEK1/2 does not induce ERK1/2 activation or the resultant
MMP-7 production under the present experimental conditions.
Since there is increasing evidence implicating an MEK1/2-
independent and protein kinase C (PKC)-dependent ERK1/2
activation pathway [38], constitutive activation of ERK1/2 in
HT-29 cells may be associated with PKC activation.
In conclusion, our results showed that citrus auraptene nota-
bly suppressed proMMP-7 production through the inhibition
of ERK1/2-regulated protein translation pathways via an ac-
tion mode apparently diﬀerent from that of rapamycin. To
our knowledge, this is the ﬁrst report of a food phytochemical
that targets protein translation through a unique mechanism.
Together with those of our previous report [20], these ﬁndings
suggest that citrus components such as nobiletin and aurap-
tene are promising candidates for chemoprevention and che-
motherapy strategies.Acknowledgement: This study was supported in part by a Grant-in-Aid
for Cancer Research from the Ministry of Health, Labor, and Welfare
of Japan (to A. M.).References
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